Brentuximab Vedotin for Systemic Sclerosis

Scleroderma Clinical Trial

— BRAVOS  

Official title:

Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis BRAVOS: A Phase 1/2 Multicenter Randomized, Double Blinded, Safety Study (ITN075AI)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03222492
• Other study ID #: DAIT ITN075AI
• Secondary ID: UM1AI109565NIAID
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: September 20, 2017
• Est. completion date: April 10, 2023

Study information

• Verified date: April 2024
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

There is significant unmet need for effective treatment options for Diffuse Cutaneous Systemic Sclerosis (dcSSc). The present study will be a dose-escalation safety trial of brentuximab vedotin, a drug-antibody conjugate approved for the treatment of lymphoma and targeted to the protein CD30 molecule expressed on activated immune cells There is evidence for CD30 involvement in SSc. This study represents the first step in determining safety and tolerability of brentuximab vedotin in SSc.

Description:

This is a multicenter prospective double blind placebo controlled dose escalation safety clinical trial with brentuximab vedotin and stable background immunosuppressive therapy in adult individuals with Diffuse Cutaneous Systemic Sclerosis (dcSSc). Adult male and female participants with dcSSc will be recruited by a collaborative group of clinical sites in the United States. Participants who meet the eligibility criteria will be enrolled without regard to gender, race, or ethnicity.

Eligible participants will be randomly assigned to study treatment, either brentuximab vedotin or placebo equivalent in a 6:2 ratio favoring brentuximab vedotin. Three dose cohorts are planned with 8 participants in each cohort, for a total of 24 participants who receive sufficient doses of the investigational medication to assess safety.

The doses planned for each ascending dose cohort include 0.6mg/kg, 1.2 mg/kg, and 1.8 mg/kg brentuximab vedotin or placebo equivalent. All cohorts will receive intravenous administration of study medication every 3 weeks for 21 weeks, for a total of eight doses. Following completion of treatment, participants will undergo follow-up visits at weeks 24, 28, 36 and 48.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: April 10, 2023
• Est. primary completion date: April 10, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Classification of Systemic Sclerosis (SSc), as defined using the 2013 American College of Rheumatology/European Union League Against Rheumatism classification of SSc;

• Diagnosis of Diffuse Cutaneous Systemic Sclerosis (dcSSc), as defined by LeRoy and Medsger, Criteria for the classification of early systemic sclerosis. J Rheumatol, 2001. 28(7): p. 1573-6;

• Disease duration = 60 months (defined as time from the first non-Raynaud phenomenon manifestation);

• Modified Rodnan Skin Score (mRSS) units = 15 and = 45, and both of the following:

• At least mild skin thickening (= 1+ mRSS) of the forearm, and

• At least moderate skin thickening (= 2+ mRSS) at the planned forearm skin biopsy site.

• Documentation of at least 12 weeks of ongoing immunosuppressive therapy for SSc at the time of enrollment, and at least 4 weeks at a stable dose, of one of the following:

• Methotrexate = 25 mg/week, or

• Mycophenolate mofetil =3 grams/day or mycophenolate sodium =2.16 grams/day, or

• Azathioprine =3mg/kg/day.

• Ability to provide informed consent.

Exclusion Criteria:

• Rheumatic disease other than Diffuse Cutaneous Systemic Sclerosis (dcSSc); it is acceptable to include patients with osteoarthritis, fibromyalgia, sicca symptoms, and scleroderma-associated myopathy;

• Limited cutaneous Systemic Sclerosis (SSc) or sine scleroderma;

• Pulmonary disease with Forced Vital Capacity (FVC) =60% of predicted, or Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) (corrected for hemoglobin) =60% of predicted;

• Pulmonary hypertension (PH) or moderate to severe left ventricular dysfunction, defined as one of the following:

• Transthoracic echocardiography demonstrating at least one of the following (unless subsequent right heart catheterization does not demonstrate PH; or unless prior right heart catheterization within one year did not demonstrate PH and echocardiography results are not significantly changed):

• Tricuspid regurgitation jet >2.8 m/sec or estimated right ventricular systolic pressure > 42 mm Hg. or

• At least one of the following:

1. Abnormality of right atrial size, shape, or wall thickness consistent with PH, or

2. Abnormality of right ventricular size, shape, or wall thickness consistent with PH, or

3. Abnormal septal wall shape consistent with PH.

• Left Ventricular Ejection Fraction (LVEF) <50%.

• Right heart catheterization showing mean pulmonary artery pressure =25 mm Hg at rest;

• Current use of approved medications for PH. It is acceptable to use phosphodiesterase type 5 (PDE-5) inhibitors for Raynaud's, digital ulcers, and intermittently for erectile dysfunction.

• Active scleroderma renal crisis within the 4 months prior to enrollment;

• History of moderate-to-severe lower gastrointestinal dysmotility such as current use of parenteral nutrition and/or recent history of intestinal pseudo-obstruction within 3 months prior to enrollment;

• The following medications:

• Oral corticosteroids >10 mg/day of prednisone or equivalent within 2 weeks prior to enrollment;

• Treatment with Intravenous Immunoglobulin (IVIG) within 12 weeks prior to enrollment;

• Treatment with cyclophosphamide within 6 months prior to enrollment;

• Use of investigational biologic or non-biologic medication within the past 90 days, or 5 half-lives prior to enrollment, whichever is greater;

• Use of anti-TNF medication or other biologic medications within the past 90 days, or 5 half-lives prior to enrollment, whichever is greater;

• Prior treatment with anti-CD20 if either of the following are true:

• B cells = lower limit of normal (LLN), or

• Treatment with anti-CD20 has been within 12 months prior to enrollment.

• Any prior treatment with cell-depleting therapies other than anti-CD20, including investigational agents, including but not limited to, CAMPATH(R), anti- CD4, anti-CD5, anti-CD3, anti-CD19; or

• Any prior treatment with chlorambucil, bone marrow transplantation, or total lymphoid irradiation.

• Receipt of a live-attenuated vaccine within 3 months of study enrollment;

• Concomitant malignancies or a history of malignancy, with the exception of adequately treated basal and squamous cell carcinoma of the skin, or carcinoma in situ of the cervix;

• Major surgery (including joint surgery) within 8 weeks prior to enrollment;

• History of solid organ or hematopoietic stem cell transplantation;

• History of primary immunodeficiency;

• Comorbidities requiring systemic corticosteroid therapy, including those which have required three or more courses of systemic corticosteroids within the 12 months prior to enrollment;

• Current substance abuse or history of substance abuse within 12 months prior to enrollment;

• History of severe depression or severe psychiatric condition;

• Lack of peripheral venous access;

• Known hypersensitivity to brentuximab vedotin, a component thereof, or the excipient contained in the drug formulation;

• Severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, or neurological disease (or, in the investigator's opinion, any other concomitant medical condition that places the participant at risk by participating in this study), including but not limited to:

• Uncompensated congestive heart failure (New York Heart Association Class III or VI);

• Clinically significant active coronary artery disease (e.g., unstable angina or acute myocardial infarction within 6 months prior to enrollment);

• Recently active cerebrovascular disease (e.g., stroke or transient ischemic attack within 6 months prior to enrollment);

• Uncontrolled systemic hypertension;

• Confirmed diagnosis of diabetes mellitus;

• Pancreatitis within 30 days prior to enrollment; or

• History or presence of peripheral neuropathy, such as mononeuritis multiplex, acute or chronic inflammatory demyelinating polyneuropathy, axonal sensorimotor neuropathies, or drug related neuropathy or neuritis.

• Evidence of infection:

• Any infected ulcer at enrollment;

• Active bacterial, viral, fungal, or opportunistic infections requiring systemic anti-infective therapy;

• Evidence of current or prior infection with tuberculosis:

• Positive QuantiFERON® - TB Gold or TB Gold Plus test results.

• Note: Purified protein derivative (PPD) tuberculin test may be substituted for QuantiFERON® - TB Gold or TB fold Plus test.

• Indeterminant QuantiFERON® - TB Gold test results, unless followed by a subsequent negative PPD or negative QuantiFERON® and clearance by local Infectious Disease department.

• Evidence of current or prior infection with:

• Human Immunodeficiency Virus (HIV), or

• Hepatitis B Virus (as assessed by hepatitis B surface antigen, HBsAg and antibody to hepatitis B core antigen, anti-HBc), or

• Hepatitis C Virus (HCV), with the exception of adequately treated HCV with documentation of sustained virologic response, defined as undetectable HCV RNA at least 12 weeks after the end of treatment.

• History of progressive multifocal leukoencephalopathy (PML);

• Hospitalization for treatment of infections, or parenteral (intravenous or intramuscular) antibacterials, antivirals, anti-fungals, or anti-parasitic agents within the past 60 days prior to enrollment;

• Chronic infection that is currently being treated with systemic suppressive antibiotic or antiviral therapy, including but not limited to tuberculosis, pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster, and atypical mycobacteria.

• History of significant infection or recurrent infection that, in the investigator's opinion, places the participant at risk by participating in this study.

• Positive polymerase chain reaction (PCR) test for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) within 14 days prior to enrollment.

• The following laboratory abnormalities:

• Neutropenia (absolute neutrophil count <1500/mm^3);

• Thrombocytopenia (platelets <100,000/mm^3);

• Moderately severe anemia (hemoglobin, Hgb < 10 g/dL);

• Liver function test (aspartate aminotransferase [AST], alanine aminotransferase [ALT], or alkaline phosphatase) results that are = 1.5 times the upper limit of normal;

• Serum total bilirubin > 1.5 times the upper limit of normal, or > 3 times the upper limit of normal in the presence of Gilbert's syndrome; or

• Serum amylase and serum lipase > 1.5 times the upper limit of normal.

• Renal dysfunction, defined as either one of the following:

• Serum creatinine > 1.5 times the upper limit of normal; or

• Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m^2.

• Pregnancy;

• Breastfeeding;

• Unwillingness to use two forms of medically acceptable contraception methods by participants and their partners (if of reproductive potential) during the study and for at least 6 months after last dose of study drug; or

• Inability to comply with study and follow-up procedures.

Related Conditions & MeSH terms

• dcSSc
• Diffuse Cutaneous Systemic Sclerosis
• Scleroderma
• Scleroderma, Diffuse
• Scleroderma, Systemic
• Sclerosis

Intervention

Biological:
• Brentuximab Vedotin
Ascending dose cohorts. All cohorts will receive intravenous administration of study medication every 3 weeks for 21 weeks, for a total of eight doses.
• Placebo
Placebo control for blinding (masking), 0.95% normal saline.

Locations

Country	Name	City	State
United States	University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology	Ann Arbor	Michigan
United States	Medical University of South Carolina: Division of Rheumatology & Immunology	Charleston	South Carolina
United States	Duke University Medical Center: Division of Rheumatology and Immunology	Durham	North Carolina
United States	University of Texas Houston Medical School: Division of Rheumatology and Clinical Immunogenetics	Houston	Texas
United States	UCLA Medical Center: Division of Rheumatology	Los Angeles	California
United States	Hospital for Special Surgery, New York: Division of Rheumatology	New York	New York
United States	University of Pittsburgh Medical Center: Division of Rheumatology and Clinical	Pittsburgh	Pennsylvania
United States	Georgetown University Medical Center: Division of Rheumatology	Washington	District of Columbia

Sponsors (5)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)	Immune Tolerance Network (ITN), PPD, Rho Federal Systems Division, Inc., Seagen Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48.	Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin.	Baseline through end of study (48 weeks for participants who complete the study)
Primary	Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48.	Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin.	Baseline through end of study (48 weeks)
Secondary	Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 12, 24, and 36.	Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin.	Baseline through Week 12 study visit or 12 weeks on study if the visit was missed. Baseline through Week 24 study visit or 24 weeks on study if the visit was missed. Baseline through Week 36 study visit or 36 weeks on study if the visit was missed
Secondary	Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week12	Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin.	Baseline through Week 12 study visit or 12 weeks on study if the visit was missed.
Secondary	Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 24.	Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin.	Baseline through Week 24 study visit or 24 weeks on study if the visit was missed.
Secondary	Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Weeks 36.	Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin.	Baseline through Week 36 study visit or 36 weeks on study if the visit was missed.
Secondary	Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12, 24, 36, and 48.	Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin.	Baseline thru Week 12 visit or 12 weeks on study if visit was missed/thru Week 24 visit or 24 weeks on study if visit was missed/thru Week 36 visit or 36 weeks on study if visit was missed/thru Week 48 visit or 48 weeks on study if visit was missed
Secondary	Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 12	Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin.	Baseline through the Week 12 study visit or 12 weeks on study if the visit was missed
Secondary	Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 24.	Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin.	Baseline through the Week 24 study visit or 24 weeks on study if the visit was missed.
Secondary	Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 36.	Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin.	Baseline through the Week 36 study visit or 36 weeks on study if the visit was missed.
Secondary	Proportion of Participants That Experience at Least One Grade 2 or Higher Adverse Event at or Before Weeks 48.	Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin.	Baseline through the Week 48 study visit or 48 weeks on study if the visit was missed.
Secondary	Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12, 24, 36, and 48.	Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe.	Baseline thru Week 12 visit or 12 weeks on study if visit was missed/thru Week 24 visit or 24 weeks on study if visit was missed/thru Week 36 visit or 36 weeks on study if visit was missed/thru Week 48 visit or 48 weeks on study if visit was missed
Secondary	Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 12	Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe.	Baseline through the Week 12 study visit or 12 weeks on study if the visit was missed.
Secondary	Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 24.	Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe.	Baseline through the Week 24 study visit or 24 weeks on study if the visit was missed.
Secondary	Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 36.	Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe.	Baseline through the Week 36 study visit or 36 weeks on study if the visit was missed.
Secondary	Proportion of Participants With Grade 2 or Higher Peripheral Neuropathy at or Before Weeks 48.	Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe.	Baseline through the Week 48 study visit or 48 weeks on study if the visit was missed.
Secondary	Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12, 24, 36, and 48.	Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe.	Baseline thru Week 12 visit or 12 weeks on study if visit was missed/thru Week 24 visit or 24 weeks on study if visit was missed/thru Week 36 visit or 36 weeks on study if visit was missed/thru Week 48 visit or 48 weeks on study if visit was missed
Secondary	Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 12	Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe.	Baseline through the Week 12 study visit or 12 weeks on study if the visit was missed.
Secondary	Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 24.	Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe.	Baseline through the Week 24 study visit or 24 weeks on study if the visit was missed.
Secondary	Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 36.	Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe.	Baseline through the Week 36 study visit or 36 weeks on study if the visit was missed.
Secondary	Proportion of Participants With Grade 3 or Higher Neutropenia at or Before Weeks 48.	Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe.	Baseline through the Week 48 study visit or 48 weeks on study if the visit was missed.
Secondary	Proportion of Participants With Any of the Following Grade 3 or Higher AEs at or Before Week 48: Peripheral Neuropathy, Neutropenia, Infectious Adverse Events, Infusions Reactions, or Progressive Multifocal Leukoencephalopathy.	Adverse events were graded using the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for the grading of liver chemistry abnormalities. The scale ranges from grade 1 through 5, with grade 1 being the least severe and grade 5 being the most severe. Liver chemistry abnormalities were graded, from 1 through 4 (with 1 being least severe and 4 being most severe) relative to the upper limit of normal (ULN) with different grades depending on whether there was an increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or blood bilirubin.	Baseline through the Week 48 study visit or 48 weeks on study if the visit was missed.

External Links

•   Immune Tolerance Network (ITN)